Publication related to RSI or an RSI staff member

Statistical methods for active pharmacovigilance, with applications to diabetes drugs.

Pharmacovigilance aims to identify adverse drug reactions using postmarket surveillance data under real-world conditions of use. Unlike passive pharmacovigilance, which is based on largely voluntary (and hence incomplete) spontaneous reports of adverse drug reactions with limited information on patient characteristics, active pharmacovigilance is based on electronic health records containing detailed information about patient populations, thereby allowing consideration of modifying factors such as polypharmacy and comorbidity, as well as sociodemographic characteristics. With the present shift toward active pharmacovigilance, statistical methods capable of addressing the complexities of such data are needed. We describe four such methods here, and demonstrate their application in the analysis of a large retrospective cohort of diabetics taking anti-hyperglycemic medications that may increase the risk of adverse cardiovascular events.

Authors

  • Zhuo, Lan, Zhuo L, a School of Mathematics and Statistics , Carleton University , Ottawa , Ontario , Canada.

  • Farrell, Patrick J, Farrell PJ,

  • McNair, Doug, McNair D,

  • Krewski, Daniel, Krewski D,

YEAR OF PUBLICATION: 2014
SOURCE: J Biopharm Stat. 2014;24(4):856-73. doi: 10.1080/10543406.2014.901338.
JOURNAL TITLE ABBREVIATION: J Biopharm Stat
JOURNAL TITLE: Journal of biopharmaceutical statistics
ISSN: 1520-5711 (Electronic) 1054-3406 (Linking)
VOLUME: 24
ISSUE: 4
PAGES: 856-73
PLACE OF PUBLICATION: England
ABSTRACT:
Pharmacovigilance aims to identify adverse drug reactions using postmarket surveillance data under real-world conditions of use. Unlike passive pharmacovigilance, which is based on largely voluntary (and hence incomplete) spontaneous reports of adverse drug reactions with limited information on patient characteristics, active pharmacovigilance is based on electronic health records containing detailed information about patient populations, thereby allowing consideration of modifying factors such as polypharmacy and comorbidity, as well as sociodemographic characteristics. With the present shift toward active pharmacovigilance, statistical methods capable of addressing the complexities of such data are needed. We describe four such methods here, and demonstrate their application in the analysis of a large retrospective cohort of diabetics taking anti-hyperglycemic medications that may increase the risk of adverse cardiovascular events.
LANGUAGE: eng
DATE OF PUBLICATION: 2014
DATE COMPLETED: 20150126
DATE REVISED: 20140515
MESH DATE: 2015/01/27 06:00
EDAT: 2014/04/05 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.1080/10543406.2014.901338 [doi]
OWNER: NLM

Related RSI Experts

Daniel Krewski

Chief Risk Scientist

Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Read More about Daniel Krewski

Douglas McNair


As a Software Engineering Fellow at RSI, Dr. McNair brings unparalleled expertise in machine learning, Bayesian modeling, and decision-support systems. He supports RSI’s most advanced projects by designing and validating AI/ML architectures that meet both regulatory standards and ethical imperatives,...
Read More about Douglas McNair